Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial

Ivan O. Rosas1*, George Diaz2, Robert L. Gottlieb3, Suzana M. Lobo4, Philip Robinson5, Bradley D. Hunter6, Adilson W. Cavalcante7, J. Scott Overcash8, Nicola A. Hanania1, Alan Skarbnik9, Julia Garcia-Diaz10, Ivan Gordeev11, Jordi Carratalà12, Oliver Gordon13, Emily Graham13, Nicholas Lewin-Koh14, Larry Tsai14, Katie Tuckwell14, Huyen Cao15, Diana Brainard15 and Julie K. Olsson14

© 2021 The Author(s)

Abstract

Purpose: Trials of tocilizumab in patients with severe COVID-19 pneumonia have demonstrated mixed results, and the role of tocilizumab in combination with other treatments is uncertain. Here we evaluated whether tocilizumab plus remdesivir provides greater benefit than remdesivir alone in patients with severe COVID-19 pneumonia.

Methods: This randomized, double-blind, placebo-controlled, multicenter trial included patients hospitalized with severe COVID-19 pneumonia requiring > 6 L/min supplemental oxygen. Patients were randomly assigned (2:1 ratio) to receive tocilizumab 8 mg/kg or placebo intravenously plus ≤ 10 days of remdesivir. The primary outcome was time from randomization to hospital discharge or “ready for discharge” (defined as category 1, assessed by the investigator on a 7-category ordinal scale of clinical status) to day 28. Patients were followed for 60 days.

Results: Among 649 enrolled patients, 434 were randomly assigned to tocilizumab plus remdesivir and 215 to placebo plus remdesivir. 566 patients (88.2%) received corticosteroids during the trial to day 28. Median time from randomization to hospital discharge or “ready for discharge” was 14 (95% CI 12–15) days with tocilizumab plus remdesivir and 14 (95% CI 11–16) days with placebo plus remdesivir [log-rank P = 0.74; Cox proportional hazards ratio 0.97 (95% CI 0.78–1.19)]. Serious adverse events occurred in 128 (29.8%) tocilizumab plus remdesivir and 72 (33.8%) placebo plus remdesivir patients; 78 (18.2%) and 42 (19.7%) patients, respectively, died by day 28.

Conclusions: Tocilizumab plus remdesivir did not shorten time to hospital discharge or “ready for discharge” to day 28 compared with placebo plus remdesivir in patients with severe COVID-19 pneumonia.

Keywords: COVID-19, Pneumonia, Remdesivir, Tocilizumab

*Correspondence: ivan.rosas@bcm.edu
1 Pulmonary, Critical Care, and Sleep Medicine, Lester and Sue Smith Chair in Lung Health, Baylor College of Medicine, 7200 Cambridge Street, Houston, TX 77030, USA
Full author information is available at the end of the article

Katie Tuckwell, Huyen Cao and Diana Brainard were affiliated with the above institutions at the time of the trial.
Introduction

Coronavirus disease 2019 (COVID-19) has rapidly developed into a global health threat since emerging in China in late 2019 [1]. Most patients experience mild disease and recover with symptomatic treatment and supportive care. However, a subset experience more severe illness necessitating hospitalization [2]. Among patients who seek medical care, approximately 20% experience complications that may progress to acute respiratory distress syndrome (ARDS), multiorgan failure, and death [3].

Tocilizumab is a humanized monoclonal anti–interleukin-6 receptor-alpha antibody. Interleukin-6 levels are often increased in patients with acute lung injury and ARDS, including those with severe COVID-19 pneumonia [4, 5]. Tocilizumab improved survival, reduced the need for mechanical ventilation, and shortened the length of hospital stay compared with standard care in 2 large open-label platform trials (REMAP-CAP and RECOVERY) [6, 7]. EMPACTA, a randomized, double-blind, placebo-controlled trial of patients hospitalized with COVID-19 pneumonia but not receiving ventilatory support, showed reduced likelihood of progression to mechanical ventilation or death with tocilizumab but no survival benefit [8]. Other randomized controlled trials have not shown survival benefit with tocilizumab [9–12], although potential clinical benefits in reduced need for mechanical ventilation, duration of intensive care unit (ICU) stay, and length of hospital stay were observed in COVACTA and CORIMUNO-TOCI 1 [9, 11]. A prospective meta-analysis of 27 randomized trials involving more than 10,000 patients hospitalized for COVID-19 demonstrated that interleukin-6 antagonists were associated with lower 28-day all-cause mortality [13]. Rapidly evolving standards of care during the COVID-19 pandemic have resulted in further uncertainty about the use of tocilizumab in combination with other treatments, including corticosteroids and remdesivir [14].

Remdesivir is a selective inhibitor of the viral RNA-dependent RNA polymerase that delays RNA chain termination during replication of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) [15] and decreases the efficiency of viral nucleotide incorporation [16]. A 10-day course of remdesivir was superior to standard care alone in reducing time to recovery in a double-blind, randomized, placebo-controlled trial of patients hospitalized with severe COVID-19 [17], and a 5-day course demonstrated clinical benefit in moderate COVID-19 [18]. We hypothesized that combining remdesivir and tocilizumab could be more effective than adding remdesivir alone to standard care, which could include corticosteroids.

Methods

Trial design and patients

REMDACTA, a randomized, double-blind, placebo-controlled, multicenter, phase 3 trial, evaluated the efficacy and safety of tocilizumab plus remdesivir versus placebo plus remdesivir in patients aged 12 years and older hospitalized with severe COVID-19 pneumonia between June 2020 and March 2021. Patients were required to have a positive SARS-CoV-2 polymerase chain reaction test result within 7 days of randomization, pneumonia confirmed by chest x-ray or computed tomography, and hypoxemia requiring > 6 L/min supplemental oxygen. The protocol was amended in September 2020 to allow enrollment of patients who received ≤ 2 doses of remdesivir before randomization. Patients were excluded if the estimated glomerular filtration rate was < 30 mL/min (including patients undergoing hemodialysis or hemofiltration) or alanine aminotransferase or aspartate aminotransferase levels were > 5 x the upper limit of normal within 24 h of screening. Patients with suspected active bacterial, fungal, viral, or other infection except COVID-19 were excluded. Systemic corticosteroids for treatment of COVID-19 pneumonia were permitted. Treatment with convalescent plasma, chloroquine or hydroxychloroquine, antivirals, biologics, and Janus kinase inhibitors during the trial was prohibited.

Informed consent was obtained from the patient or legally authorized representative. The trial was conducted in accordance with the ICH E6 guidance for Good Clinical Practice and the principles of the Declaration of Helsinki or local laws and regulations, whichever afforded greater protection. The trial was approved by the institutional review board or ethics committee at each site. The sponsor, F. Hoffmann-La Roche Ltd., designed the trial and performed analyses; a contract research organization paid by the sponsor monitored the trial under the direction and supervision of the sponsor.

Eligible patients were randomly assigned in a 2:1 ratio using an interactive web-based response system and a permuted block method to receive blinded treatment with tocilizumab plus remdesivir or placebo plus remdesivir. Randomization was stratified by geographic region.
(North America, Europe, other) and by a 2-level factor based on clinical status at screening (ordinal scale categories 4–5, category 6) on a 7-category ordinal scale (additional details are in the Online Resource). Remdesivir was administered intravenously, followed by a single intravenous dose of tocilizumab 8 mg/kg (maximum, 800 mg) or placebo on day 1. Patients with sustained fever or clinically significant worsening of signs and symptoms of COVID-19 (e.g., increased supplemental oxygen requirement) could receive a second infusion of blinded tocilizumab or placebo within 8 to 24 h of the first infusion. Patients were monitored through day 60, and the primary end point was assessed at day 28. Additional details and the complete trial protocol are in the Online Resource. The trial is registered on ClinicalTrials.gov (https://clinicaltrials.gov/ct2/show/NCT04409262).

Outcomes
The primary outcome was time from randomization to hospital discharge or “ready for discharge,” defined as category 1, assessed by the investigator on the 7-category ordinal scale to day 28. Patients achieved the outcome at the time of discharge or when they achieved category 1 on the 7-category ordinal scale, whichever occurred first, provided they had no further ordinal scale assessments greater than category 1 on or before day 28, they were not readmitted to the hospital on or before day 28, and they did not die on or before day 28.

The primary outcome was initially defined as clinical status assessed by the investigator using a 7-category ordinal scale of clinical status on day 28, but this was changed to time from randomization to hospital discharge or “ready for discharge” to day 28 in response to evolving external data, including results from COVACTA and EMPACTA, which suggested that time to discharge was a more sensitive outcome for trials in this patient population [8, 9]. The amendment was finalized in September 2020, and the original primary outcome was retained as a secondary outcome. Ordinal scale categories are as follows: 1, discharged or “ready for discharge” (as evidenced by normal body temperature and respiratory rate, and stable oxygen saturation on ambient air or $\leq 2$ L/min supplemental oxygen); 2, non–ICU hospital ward, not requiring supplemental oxygen; 3, non–ICU hospital ward, requiring supplemental oxygen; 4, ICU or non–ICU hospital ward, requiring noninvasive ventilation or high-flow oxygen; 5, ICU, requiring intubation and mechanical ventilation; 6, ICU, requiring extracorporeal membrane oxygenation or mechanical ventilation and additional organ support; 7, death. Key secondary efficacy outcomes assessed to day 28 were time from randomization to mechanical ventilation or death, clinical status on the ordinal scale at day 14, and time to death. Mortality was assessed at day 28 and day 60. Adverse events were recorded according to the Medical Dictionary for Regulatory Activities, version 23.1.

Statistical analysis
Assuming a median time to hospital discharge or “ready for discharge” of 11 days in the placebo plus remdesivir arm [17], a sample size of 650 patients accruing approximately 520 events was calculated to provide 80% power to detect a hazard ratio of 1.3 or an approximate 2.5-day reduction in median time to hospital discharge or “ready for discharge” for tocilizumab plus remdesivir.

Efficacy was assessed in the modified intention-to-treat population, defined as all randomly assigned patients who received any amount of tocilizumab or placebo grouped according to randomly assigned treatment arm. Safety was assessed in the safety-evaluable population, defined as all patients who received any amount of study medication (remdesivir, tocilizumab/placebo) according to treatment received.

The primary outcome was compared between the treatment arms using a log-rank test stratified by region (North America, Europe, other) and baseline ordinal scale category (4–5, 6). Treatment arms were compared using a Cox proportional hazards model adjusted for stratification factors. Patients who died on or before day 28 were censored at day 28, and patients who withdrew or were lost to follow-up before achieving the primary outcome (not followed by death) were censored at their last recorded ordinal scale assessment. The primary end point was tested at a 2-sided 5% significance level. Kaplan–Meier plots, medians, 95% CIs, and $P$ values from the stratified log-rank test were calculated for time-to-event primary and secondary efficacy outcomes, and distributions were compared using the Cox model. Ordinal data were analyzed using a proportional odds model comparing treatment arms and accounting for stratification factors at randomization. Effect sizes, $P$ values, and 95% CIs were calculated based on odds ratios for treatment effect from the proportional odds model. The Cochran–Mantel–Haenszel test adjusted by the stratification factors at randomization was used to analyze mortality at day 28 and day 60. Additional details are in the Online Resource.

Results
Patients
Overall, 709 patients were screened and 649 were enrolled from Brazil ($n = 154$ (23.7%)), Russia ($n = 49$ (7.6%)), Spain ($n = 14$ (2.2%)), and the United States ($n = 432$ (66.6%)) between June 2020 and January 2021 at 53 trial sites; 434 were randomly assigned to the tocilizumab plus remdesivir arm and 215 to the placebo plus
remdesivir arm (Fig. 1). Four patients in the tocilizumab plus remdesivir arm and five patients in the placebo plus remdesivir arm did not receive tocilizumab or placebo and were excluded from the modified intention-to-treat population (additional details on the analysis populations are in the Online Resource). Approximately three-quarters of patients completed the trial to day 28: 336 (77.4%) in the tocilizumab plus remdesivir arm and 160 (74.4%) in the placebo plus remdesivir arm. Death was the most common reason for not completing the trial; 78 patients (18%) in the tocilizumab plus remdesivir arm and 42 (19.5%) in the placebo plus remdesivir arm died on or before day 28. Among the remaining patients, in the tocilizumab plus remdesivir arm, 9 (2.1%) were lost to follow-up, 7 (1.6%) withdrew consent, 2 (0.5%) discontinued because of adverse events, 1 (0.2%) discontinued...
following a protocol deviation, and 1 (0.2%) discontinued for other reasons that were not specified; in the placebo plus remdesivir arm, 7 patients (3.3%) were lost to follow-up, 3 (1.4%) withdrew consent, and 3 (1.4%) discontinued following protocol deviations (Fig. 1).

A second dose of tocilizumab or placebo was administered to 85 patients (19.8%) in the tocilizumab plus remdesivir arm and 48 (22.7%) in the placebo plus remdesivir arm (safety population) 8 to 24 h after the first tocilizumab/placebo dose for sustained fever or clinically significant worsening of signs or symptoms. Among all randomly assigned patients, 266 (41%) discontinued remdesivir early, 171 (39.4%) in the tocilizumab plus remdesivir arm, and 95 (44.2%) in the placebo plus remdesivir arm. The most common reason for continuing remdesivir was discharge from the study hospital before completing 10 days of treatment [tocilizumab plus remdesivir, 99 patients (22.8%); placebo plus remdesivir, 55 patients (25.6%)].

Demographics and disease characteristics at baseline were generally well balanced between treatment arms (Table 1). Most patients were at ordinal scale category 4 at baseline [tocilizumab plus remdesivir, 336 (78.1%); placebo plus remdesivir, 378/429 (88.1%); safety population]. Similar proportions of patients received remdesivir before randomization (tocilizumab plus remdesivir, 19.3%; placebo plus remdesivir, 25.6%). Most patients received systemic corticosteroids at baseline [tocilizumab plus remdesivir, 357/429 (83.2%); placebo plus remdesivir 184/213 (86.4%); safety population] or during the trial to day 28 [tocilizumab plus remdesivir, 378/429 (88.1%); placebo plus remdesivir 188/213 (88.3%); safety population].

Primary outcome
Median time from randomization to hospital discharge or “ready for discharge” to day 28 was 14 (95% CI 12–15) days in the tocilizumab plus remdesivir arm and 14 (95% CI 11–16) days in the placebo plus remdesivir arm [log-rank \( P=0.74 \); Cox proportional hazards ratio 0.97 (95% CI 0.78–1.19)] (Fig. 2a, Table 2). The proportion of patients discharged or “ready for discharge” to day 28 was 66% in the tocilizumab plus remdesivir arm and 67.1% in the placebo plus remdesivir arm. There were no significant differences in time to hospital discharge or “ready for discharge” between treatment arms among subgroups of patients according to demographics, corticosteroid use at baseline, remdesivir use before randomization, or mechanical ventilation at baseline. Time to hospital discharge or “ready for discharge” did not differ according to baseline ordinal scale category except among patients in ordinal category 5 at baseline (39 in the tocilizumab plus remdesivir group, 9 in the placebo plus remdesivir group) for whom tocilizumab was associated with longer time to discharge [hazard ratio 0.36 (95% CI 0.14–0.91)]; however, the small number of patients in this subgroup limits interpretability (Online Resource Fig. S1). No difference was observed between treatment arms for the original primary outcome: clinical status at day 28 on the 7-category ordinal scale (Online Resource Fig. S2).

Secondary outcomes
Mechanical ventilation or death to day 28 occurred in 123 patients (28.6%) in the tocilizumab plus remdesivir arm and 61 patients (29%) in the placebo plus remdesivir arm. Median time to mechanical ventilation or death to day 28 was nonevaluable in both treatment arms because it occurred in less than half the patients [log-rank \( P=0.90 \); hazard ratio 0.98 (95% CI 0.72–1.34)] (Fig. 2b, Table 2). Mean clinical status on the 7-category ordinal scale at day 14 was 2.8 (95% CI 2.6–3) in the tocilizumab plus remdesivir arm and 2.9 (95% CI 2.6–3.2) in the placebo plus remdesivir arm [difference –0.07 (–0.4, 0.3); \( P=0.72 \) (Table 2) because the assumption of proportional odds was not met (Online Resource Table S1), the prespecified difference in means analysis is presented]. Proportions of patients in each ordinal scale category at day 14 were similar between treatment arms (Table 2, Online Resource Fig. S3). Seventy-eight patients (18.1%) in the tocilizumab plus remdesivir arm and 41 (19.5%) in the placebo plus remdesivir arm died by day 28 [weighted difference –1.3% (95% CI –7.8%, 5.2%); \( P=0.69 \)]. Median time to death was nonevaluable in both arms [log-rank \( P=0.79 \); hazard ratio 0.95 (95% CI 0.65–1.39)] (Fig. 2c, Table 2). No significant difference was observed in time to death to day 28 between treatment arms among subgroups of patients based on demographics, corticosteroid use at baseline, remdesivir use before randomization, or mechanical ventilation at baseline (Online Resource Fig. S1). By day 60, 97 patients (22.6%) in the tocilizumab plus remdesivir arm and 54 (25.7%) in the placebo plus remdesivir arm had died [weighted difference –3% (95% CI –10.1%, 4%); \( P=0.39 \)].

Safety to day 28
In the safety population, the number of patients who experienced ≥1 adverse event was 320 of 429 (74.6%) in the tocilizumab plus remdesivir arm and 147 of 213 (69%) in the placebo plus remdesivir arm. Serious adverse events were reported in 128 patients (29.8%) in the tocilizumab plus remdesivir arm and 72 (33.8%) in the placebo plus remdesivir arm (Table 3, Online Resource Table S2). Forty-six patients (10.7%) in the tocilizumab plus remdesivir arm and 28 (13.1%) in the placebo plus remdesivir arm discontinued treatment because of an adverse event. Adverse events of special interest were balanced between both treatment arms, including serious infections [86
### Table 1 Baseline demographics and disease characteristics (modified intention-to-treat population)

| Characteristic                                           | Tocilizumab + remdesivir | Placebo + remdesivir |
|----------------------------------------------------------|--------------------------|----------------------|
| N = 430                                                  |                          | N = 210              |
| **Sex**                                                  |                          |                      |
| Male                                                     | 266 (61.9)               | 139 (66.2)           |
| Female                                                   | 164 (38.1)               | 71 (33.8)            |
| **Age, years**                                           |                          |                      |
| Mean ± SD                                                | 60.1 ± 13.3              | 58.2 ± 13.3          |
| 18–64                                                    | 257 (59.8)               | 138 (65.7)           |
| 65–84                                                    | 165 (38.4)               | 70 (33.3)            |
| ≥ 85                                                     | 8 (1.9)                  | 2 (1)                |
| **Ethnicity**                                            |                          |                      |
| Hispanic or Latino                                       | 208 (48.4)               | 122 (58.1)           |
| Not Hispanic or Latino                                   | 207 (48.1)               | 86 (41)              |
| Unknown/not stated                                       | 15 (3.5)                 | 2 (1)                |
| **Race**                                                 |                          |                      |
| White                                                    | 279 (64.9)               | 150 (71.4)           |
| Black or African American                                | 51 (11.9)                | 19 (9)               |
| Asian                                                    | 17 (4)                   | 5 (2.4)              |
| Native Hawaiian or Other Pacific Islander                | 7 (1.6)                  | 3 (1.4)              |
| American Indian or Alaska Native                         | 4 (0.9)                  | 4 (1.9)              |
| Multiple                                                 | 9 (2.1)                  | 2 (1)                |
| Unknown                                                  | 63 (14.7)                | 27 (12.9)            |
| **Weight, kg, mean ± SD**                                | 94.4 ± 26.5              | 96.4 ± 25.3          |
| **NEWS2,a mean ± SD**                                    | 6.5 ± 2.3                | 64.2 ± 2.4           |
| **Ordinal scale for clinical status**b                   |                          |                      |
| 3                                                        | 29 (6.7)                 | 13 (6.2)             |
| 4                                                        | 336 (78.1)               | 175 (83.3)           |
| 5                                                        | 39 (9.1)                 | 9 (4.3)              |
| 6                                                        | 26 (6)                   | 13 (6.2)             |
| **Mechanical ventilationc**                              | 59 (13.7)                | 22 (10.5)            |
| **Corticosteroid use (safety population), n/N (%)**      |                          |                      |
| Baselined                                                | 357/429 (83.2)           | 184/213 (86.4)       |
| During the trial to day 28e                              | 378/429 (88.1)           | 188/213 (88.3)       |
| Remdesivir use before randomization                      | 83 (19.3)                | 40 (19)              |
| Days, mean ± SD                                          | 1.3 ± 0.7                | 1.5 ± 0.6            |
| **Coexisting conditions**                                |                          |                      |
| Diabetes                                                 | 172 (40)                 | 81 (38.6)            |
| Heart disease                                            | 105 (24.4)               | 45 (21.4)            |
| Hypertension                                             | 267 (62.1)               | 128 (61)             |
| Time since first COVID-19 symptom, days, mean ± SD       | 8.8 ± 4.8                | 8.9 ± 4.7            |
| **Symptoms at time of COVID-19 diagnosis**               |                          |                      |
| Fever                                                    | 279 (64.9)               | 142 (67.6)           |
| Cough                                                    | 313 (72.8)               | 158 (75.2)           |
| Shortness of breath                                      | 348 (80.9)               | 174 (82.9)           |
| Gastrointestinal symptoms                                | 139 (32.3)               | 62 (29.5)            |
| Headache                                                 | 84 (19.5)                | 34 (16.2)            |
| Fatigue                                                  | 178 (41.4)               | 79 (37.6)            |
| Anosmia                                                  | 62 (14.4)                | 26 (12.4)            |
| Other                                                    | 159 (37)                 | 77 (36.7)            |
ing evolution of standard care. In EMPACTA, which background treatments, in part because of the continued differed with respect to target patient population and trials of tocilizumab in severe COVID-19, REMDACTA were balanced between the treatment arms and consisted including the incidence and types of serious infections, which was consistent with the known disease course of severe COVID-19. Signals were identified in this trial, and the safety profile demonstrated a treatment benefit on time to mechanical ventilation or death for tocilizumab versus placebo, 64.2% of patients were receiving low-flow oxygen at enrollment, 54.6% received remdesivir, and >80% received systemic corticosteroids. COVACTA recruited patients with a broader range of disease severity, and fewer patients received effective background therapy (<10% of patients received remdesivir, <50% received corticosteroids). These differences in patient selection and treatments may account for the different outcomes between the studies.

**Table 1 (continued)**

ICU intensive care unit, NEWS2 National Early Warning Score

| Data are shown as number (%) unless noted otherwise |
|-----------------------------------------------------|
| a NEWS2 was not calculated if ≥ 1 of the components was missing |
| b 1, Discharged (or “ready for discharge”); 2, Non-ICU hospital ward (or “ready for hospital ward”) not requiring supplemental oxygen; 3, Non-ICU hospital ward (or “ready for hospital ward”) requiring supplemental oxygen; 4, ICU or non-ICU hospital ward, requiring noninvasive ventilation or high-flow oxygen; 5, ICU, requiring intubation and mechanical ventilation; 6, ICU, requiring extracorporeal membrane oxygenation or mechanical ventilation and additional organ support. 7, Death |
| c The baseline mechanical ventilation record was missing for 1 patient, so the baseline ordinal scale category (category 3: non-ICU hospital ward or “ready for hospital ward” requiring supplemental oxygen) was used to impute baseline mechanical ventilation status as not on mechanical ventilation |
| d Medications received between day –7 and day 1. Includes only systemic treatments |
| e Medications started before or after day 1 and ending on or after day 1 up to day 28. Includes only systemic treatments |

(20%) and 53 (24.9%) and serious bleeding events [11 (2.6%) and 7 (3.3%)]. The most common serious infections (reported in >1% of patients in each treatment arm) were progression of underlying COVID-19 pneumonia (required to be reported as a serious adverse event if COVID-19 resulted in death), septic shock, pneumonia, sepsis, and bacterial pneumonia.

**Discussion**

In this trial, there was no difference between tocilizumab plus remdesivir and placebo plus remdesivir in time from randomization to hospital discharge or “ready for discharge” to day 28. There were also no differences between treatment arms in the key secondary outcomes of time to mechanical ventilation or death to day 28, clinical status at day 14 assessed by the investigator on the 7-category ordinal scale, and time to death to day 28. No new safety signals were identified in this trial, and the safety profile was consistent with the known safety profiles of tocilizumab and remdesivir. Adverse events of special interest, including the incidence and types of serious infections, were balanced between the treatment arms and consistent with the known disease course of severe COVID-19.

Compared with other randomized placebo-controlled trials of tocilizumab in severe COVID-19, REMDACTA differed with respect to target patient population and background treatments, in part because of the continuing evolution of standard care. In EMPACTA, which demonstrated a treatment benefit on time to mechanical ventilation or death for tocilizumab versus placebo, 64.2% of patients were receiving low-flow oxygen at enrollment, 54.6% received remdesivir, and >80% received systemic corticosteroids. COVACTA recruited patients with a broader range of disease severity, and fewer patients received effective background therapy (<10% of patients received remdesivir, <50% received corticosteroids). These differences in patient selection and treatments may account for the different outcomes between the studies.

Based on results of the REMAP-CAP [6] and RECOVERY [7] open-label platform trials, tocilizumab in combination with dexamethasone is recommended by the National Institutes of Health COVID-19 Treatment Guidelines Panel in certain patients hospitalized with COVID-19 who exhibit rapid respiratory decompensation and, at a minimum, need for high-flow oxygen supplementation [19]. In RECOVERY, patients considered for random allocation to the tocilizumab arm were required to have clinical evidence of progressive COVID-19 after their first random allocation in the trial. In REMAP-CAP, patients were enrolled within 24 h of initiation of organ support in the ICU, defined as invasive or noninvasive mechanical ventilation (including high-flow nasal cannula with flow rate >30 L/min of and fraction of inspired oxygen >0.4) or intravenous infusion of any vasopressor or inotrope. REMDACTA enrolled patients who required >6 L/min of supplemental oxygen.

(See figure on next page.)

**Fig. 2** Time to (a) hospital discharge or “ready for discharge” (primary outcome), (b) mechanical ventilation or death, (c) death. Data are shown as a 1 minus the Kaplan–Meier curve, b Kaplan–Meier curve for time to mechanical ventilation or death, and c Kaplan–Meier curve for time to death (modified intention-to-treat population). Panel a shows time to hospital discharge or “ready for discharge” defined as days from randomization to hospital discharge or “ready for discharge” not followed by ordinal scale category >1, hospital readmission, or death. Patients who discontinued or were lost to follow-up for any reason before hospital discharge or “ready for discharge” criteria were met were censored at their last recorded ordinal scale assessment. Panel b shows time to mechanical ventilation or death defined as the time from randomization to the first occurrence of death or mechanical ventilation. For patients already receiving mechanical ventilation at baseline, only death was counted as an event. One patient had a missing baseline mechanical ventilation record; therefore, the baseline ordinal scale category (category 3: non-ICU hospital ward or “ready for hospital ward” requiring supplemental oxygen) was used to impute baseline mechanical ventilation status as not receiving mechanical ventilation. Patients who withdrew or were lost to follow-up before discharge (not followed by death) were censored at their last assessment of vital signs. Patients who withdrew or were lost to follow-up on or after the day of discharge (not followed by death or hospital readmission) were censored at day 28. Panel c shows time to death defined as the time from randomization to death. Patients who withdrew or were lost to follow-up before discharge (not followed by death) were censored at the last known date they were alive. Patients who withdrew or were lost to follow-up on or after the day of discharge (not followed by death or hospital readmission) were censored at day 28. ICU intensive care unit.
Fig. 2 (See legend on previous page.)
### Table 2  Primary and key secondary efficacy outcomes

|                              | Tocilizumab + remdesivir | Placebo + remdesivir |
|------------------------------|--------------------------|----------------------|
| **Primary outcome**          |                          |                      |
| Time to hospital discharge or “ready for discharge” to day 28, days, median (95% CI)\(^a\) | 14 (12–15)                | 14 (11–16)            |
| \(P\) value                 | \(P = 0.74\)             |                      |
| Hazard ratio (95% CI)\(^b\)  | 0.97 (0.78–1.19)         |                      |
| **Secondary outcomes**\(^c\) |                          |                      |
| Time to mechanical ventilation or death to day 28, days, median (95% CI)\(^d\) | NE                      | NE                  |
| \(P\) value                 | \(P = 0.9\)              |                      |
| Hazard ratio (95% CI)\(^d\)  | 0.98 (0.72–1.34)         |                      |
| Clinical status at day 14 assessed on the 7‑category ordinal scale, n (%)\(^e\) | |                      |
| 1                            | 231 (54)                 | 110 (52.4)           |
| 2                            | 11 (2.6)                 | 4 (1.9)              |
| 3                            | 38 (8.9)                 | 24 (11.4)            |
| 4                            | 41 (9.6)                 | 14 (6.7)             |
| 5                            | 21 (4.9)                 | 14 (6.7)             |
| 6                            | 43 (10)                  | 24 (11.4)            |
| 7                            | 43 (10)                  | 20 (9.5)             |
| Clinical status at day 14 assessed on the 7‑category ordinal scale, mean (95% CI)\(^f\) | |                      |
| 1                            | 2.8 (2.6–3)              | 2.9 (2.6–3.2)        |
| Difference \(= –0.065 (–0.42 to 0.29)\) | \(P = 0.72\)            |                      |
| Time to death to day 28, days, median (95% CI)\(^g\) | NE                      | NE                  |
| \(P\) value                 | \(P = 0.79\)             |                      |
| Hazard ratio (95% CI)\(^g\)  | 0.95 (0.65–1.39)         |                      |
| Mortality at day 28, n (%) [95% CI]\(^h\) | 78 (18.1) [14.5–21.8]    | 41 (19.5) [14.2–24.9] |
| Weighted difference \(= –1.3 [–7.8 to 5.2]\) | \(P = 0.69\)            |                      |
| Mortality at day 60, n (%) [95% CI]\(^h\) | 97 (22.6) [18.6–26.5]    | 54 (25.7) [19.8–31.6] |
| Weighted difference \(= –3 [–10.1 to 4]\) | \(P = 0.39\)            |                      |

\(^a\) Time to hospital discharge or “ready for discharge” was defined as days from randomization to hospital discharge or “ready for discharge” not followed by ordinal scale category > 1, hospital readmission, or death. Patients who discontinued or were lost to follow-up for any reason before hospital discharge or “ready for discharge” criteria were met were censored at their last recorded ordinal scale assessment. Patients who died were censored at day 28.

\(^b\) Hazard ratio > 1 favors tocilizumab plus remdesivir over placebo plus remdesivir.

\(^c\) Additional outcomes were specified in the protocol (Online Resource Table S3); to facilitate rapid publication of study results, only the primary and key secondary outcomes are reported here.

\(^d\) Hazard ratio < 1 favors tocilizumab plus remdesivir over placebo plus remdesivir.

\(^e\) Missing data were imputed using last postbaseline observation carried forward. Two patients in the tocilizumab plus remdesivir arm did not have ordinal scale data after baseline to day 14.

\(^f\) Difference between mean and \(P\) value was calculated using a linear regression approach with Huber–White sandwich estimates for standard errors, including both stratification factors at randomization, baseline ordinal score (4–5, 6) and region (North America, Europe, other).

\(^g\) Weighted difference between percentage and \(P\) value was calculated using the Cochran–Mantel–Haenszel test adjusted by stratification factors at randomization ICU intensive care unit, NE nonevaluable.
irrespective of time since symptom onset time since or since diagnosis of COVID-19 and evidence of recent or rapid deterioration was not required. Together, these findings suggest that patients with declining respiratory status may be more likely to benefit from treatment with tocilizumab. Additional studies are needed to confirm this hypothesis.

The endorsement of interleukin-6 receptor blockade in patients with severe and critical COVID-19 by the World Health Organization and others will likely increase the adoption of tocilizumab as standard of care in these patients [14]. Although trials of remdesivir have not demonstrated a clear mortality benefit [20], remdesivir remains standard of care in many parts of the world based on trials that demonstrated shortened time to recovery and other clinical benefits [17, 18]. Only 27% of patients in RECOVERY and 33% of patients in REMAP-CAPE received remdesivir. Thus, it is important to better understand the role of tocilizumab in combination with remdesivir and other treatments, including newer antivirals, neutralizing antibodies, and other immunomodulators. Additional studies or patient-level meta-analyses may be required to achieve this [21].

Strengths and weaknesses

To our knowledge, REMDACTA is the first multicenter, double-blind, randomized, placebo-controlled trial to investigate the inhibition of interleukin-6 signaling in patients with COVID-19, all of whom received remdesivir and most of whom also received systemic corticosteroids. However, REMDACTA was not powered to detect the relatively small but clinically meaningful mortality benefit demonstrated in larger platform studies. REMDACTA was designed and initiated relatively early in the pandemic, before results from other randomized controlled trials of tocilizumab were available. Thus, the primary outcome of the trial was changed from clinical status on the ordinal scale to time to discharge or “ready for discharge” when enrollment was approximately half-completed based on the results from other trials, which suggested that time to discharge or “ready for discharge” is a more sensitive and clinically meaningful outcome in patients with severe COVID-19 [8, 9]. REMDACTA eligibility criteria were also modified to allow enrollment of patients who had received up to 2 doses of remdesivir before randomization because remdesivir was increasingly administered as standard of care. These changes were implemented while patients were still enrolling in the trial, and the protocol and statistical analysis plan were finalized on February 22, 2021, before unblinding on March 1, 2021.

Despite randomization, there were some slight imbalances in baseline characteristics between the treatment arms (e.g., more patients aged 65 and older, more patients requiring invasive mechanical ventilation, and fewer patients receiving corticosteroids in the tocilizumab plus remdesivir arm). These imbalances were unlikely to have been important individually but could have created

| Table 3  Safety to day 28 |
|--------------------------|
| **Adverse events**        |
| Events, n                  |
| Patients with ≥ 1 event    |
| Patients with ≥ 1 serious adverse event   |
| Deaths                     |
| Patients who discontinued the trial because of an adverse event^a  |
| Patients who discontinued study treatment because of an adverse event^b  |
| **Adverse events of special interest** |
| Events, n                  |
| Patients with ≥ 1 event    |
| Infectious                 |
| Serious infections         |
| Opportunistic infections   |
| Bleeding events            |
| Serious bleeding events    |
| Stroke                     |
| Hepatic events             |
| Anaphylactic reaction^c    |
| Hypersensitivity event^d   |
| Gastrointestinal perforations |
| Myocardial infarction      |
| Demyelinating events       |
| Potential Hy’s law cases^e |

Data are shown as number (%) of patients unless stated otherwise and percentages are calculated based on the total number of patients in each treatment arm (N).

---

^a Excluding patients who died

^b Includes discontinuation from tocilizumab/placebo and remdesivir

^c Anaphylactic reaction adverse events were identified using the narrow Standardized MedDRA Query of “Anaphylactic Reaction” that occurred during or within 24 h of the end of an infusion (tocilizumab/placebo or remdesivir). The adverse event term for both events was “Shock,” and both events occurred within 24 h of a remdesivir infusion

^d Not included in the overall number of patients with or the total count of adverse events of special interest. Hypersensitivity adverse events were identified by the narrow Standardized MedDRA Query of “Hypersensitivity” occurring during or within 24 h of the end of an infusion that were not deemed unrelated to study treatment (tocilizumab/placebo or remdesivir). The adverse event term was “Injection site urticaria” and occurred during a remdesivir infusion

^e Alanine aminotransferase or aspartate aminotransferase level > 3 × upper limit of normal and either bilirubin level > 2 × upper limit of normal or clinical jaundice, as reported by the investigator

MedDRA Medical Dictionary for Regulatory Activities
a cumulative bias in favor of placebo plus remdesivir. A slightly higher proportion of patients in the placebo plus remdesivir arm than the tocilizumab plus remdesivir arm discontinued remdesivir before completing 10 days of treatment (44.2% vs 39.4%); however, most of these early discontinuations were the result of hospital discharge, consistent with remdesivir use in other trials [17] and in clinical practice.

Conclusion
In this randomized, double-blind, placebo-controlled trial, tocilizumab plus remdesivir did not shorten time to hospital discharge or “ready for discharge” to day 28 compared with placebo plus remdesivir in patients with severe COVID-19 pneumonia, most of whom received systemic corticosteroids. Serious infections were not more frequent with tocilizumab treatment, and no new safety signals were identified.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1007/s00134-021-06507-x.

Author details
1 Pulmonary, Critical Care, and Sleep Medicine, Lester and Sue Smith Chair in Lung Health, Baylor College of Medicine, 7200 Cambridge Street, Houston, TX 77030, USA. 2 Providence Regional Medical Center Everett, Everett, WA, USA. 3 Baylor University Medical Center, Baylor Scott and White Research Institute, Dallas, TX, USA. 4 Hospital de Base de São José Do Rio Preto, São José Do Rio Preto, Brazil. 5 Hoag Hospital, Irvine, CA, USA. 6 Intermountain Healthcare, Salt Lake City, UT, USA. 7 Centro Multidisciplinary de Estudios Clinicos, São Bernardo do Campo, Brazil. 8 Velocity Clinical Research, San Diego, CA, USA. 9 Novant Health Cancer Institute, Charlotte, NC, USA. 10 Ochsner Clinical Foundation, New Orleans, LA, USA. 11 City Clinic Hospital No. 15, Moscow, Russian Federation. 12 Bellvitge University Hospital, Bellvitge Biomedical Research Institute, Universi-
daty of Barcelona, and Spanish Network for Research in Infectious Diseases, Barcelona, Spain. 13 Roche Products Ltd, Welwyn Garden City, UK. 14 Genen
tech, South San Francisco, CA, USA. 15 Gilead Sciences, Foster City, CA, USA.

Acknowledgements
The first draft of the manuscript was written with medical writing support provided by Sara Duggan, PhD, of ApotheCom; this support was funded by Hoffmann-La Roche Ltd.

REMADCTA Investigators: BRAZIL - CEMEC - Centro Multidisciplinary de Estudos Clinicos, São Bernardo Do Campo: Adilson Joaquim Westheimer Cavalcante, Loni Dorigo, Julia Minghini, Marina Miranda, Julia Ribeiro, Priscila Barbosa, Hospital de Base, São José Do Rio Preto: Suzana Margareth Lobo, Graziela Bernadin Luckemeyer, Paula Spinasse Borges, Fernando Henrique Scatena Garcia, Tamiris Moomaz, Luana Machado, Juliane Garcia, Ana Carolina Affonso, Keulle Candido, Gabriella Navarro, Gabriela Taparo, Danelli Frasatto, Maria Fernanda Santos; Hospital Nossa Senhora das Graças, Curitiba: Clovis Cunha, Fernando Pedrosso, Gustavo Giarovini, Maicon Pinto, Allain Silva, Eduardo Detgel, Murilo Henrique Guedes, Ana Paula Cunha, Aciçéna Maximo, Gisele Padilha, Kelly Ferreira, Instituto de Infectologia Emilio Ribas, São Paulo: Tânia Newman Lobato Souza, Maria Silvia Biagiotti Santos, Ana Luiza de Castro Conde Toscano, Bernardo Porto Maia, Gustavo Dittmar, Denise Pelusso, Luciana Borges, Mario Gonzalez, Anna Karina Mostachio, Luiz Carlos Pereira Junior; Instituto de Pesquisa Clínica Evandro Chagas FIOCRUZ, Rio de Janeiro: Beatriz Grinszttein, Sandra Wagner Cardoso, Isabel Mendes, Isabel Tavares, Rafael Fraha, Mimique Silveira, Mariah Pires, Maria Pia Diniz Ribeiro, Rodrigo Escada, Larissa Melo Vililela, Gabriela Robleda, Luciana Santoro Salgado, Jessica Felic; Instituto do Coração - HCFMUSP, São Paulo: Ludhmila Abrahão Hajjar, Fernando Oliveira, Fernanda Andrade, Thalita Gonzales, Brenno Rizerio Gomes, Katia Sansivieri, Alexandra Vieira; Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte: Antonio Tarcísio de Faria Freire, Douglas Dias e Silva, Alexandre Barros, Claudia Oliveira, Thayse Kayser, Flavia Medeiros, Grazielle Vieira, Daniela Pereira Mendes, Jaqueline Soares de Oliveira Gualberto, Viviane Santos, Joélima Souza. RUSSIAN FEDERATION - City Clinical Hospital #52, Moscow: Darina Fominia, Maryana Lysenko, City Pokrovskaya Hospital, St. Petersburg: Alexander Vishnevskiy, Eugeny Morozov, Dmitry Nikolaev, Anton Szovz, Maria Kiseleva, Mikhail Terskih, Medsi Clinic, Moscow: Anastasiya Mochalova, Miraakhmed Alekseev, Armen Oganesyan, Viktoria Mikhailova, City Clinical Hospital No. 15, Moscow: Ivan Gorodeev, Kseniya Polubatovnba, Kseniya Komissarova, Vitaly Firstov, Vartan Grigoryan, Ilya Korokin, Nataliya Svorzova, Anna Kozlova, Sevinch Mamedgusiyevna, Valentin Korokin, Nina Lapochkina. SPAIN - Hosp
tal General Universitario de Guadalajara, Guadalajara: Olga Mediano, Pilar Resano, Ana Ampuero, Sofia RomeroPeralta, Rosalv Mediano, Laura Silgado Martinez, Esther Viejo, Bellvitge University Hospital, L’Hospitalet de Llobregat: Jordi Carratalá, Alexander Rombaux, Gabriella AbelaIloaon, Elena Fabra, Hospital Universitario Fundación Jiméniz Diaz-Universidad Autonóma de Madrid, Madrid: Miguel Górgolas Hernández-Mora, Awa Vealeed Mohammed Al-Hayani, Alfonso Cabello Ubeda, Laura Prieto Perez, Beatriz Álvez Álvarez, Irene Carrillo Acosta, Cristina Algar Arevalo, Inmaculada Burillo, Marta Fernández Pinilla, Hospital Universitario HM Torrelodones, Torrelodones: Pablo Alejandro Cardinal Fernandez, Eduardo Dominguez, Gema Aguila, Mercedes Vilareal, Manuel Francisco Gil, Adrian Nieto, Hospital Universitario Principe de Asturias, Alcala de Henares: Jose Sanz Moreno, Maria Novella-Mena, Cristina Hernandez-Gutierrez. UNITED STATES OF AMERICA - Advocate Christ Medical Center, Oak Lawn, IL: Kenneth Dodd, David Barounis, Michael Tekippe, Ronda Oram, Adam Treitman, Valerie Griffith, Kathy Hesse, Collene Valenti, Mary Murray, Nicole Hangan, Muthu Sree, Paul Maze, Christopher Doherty, Sherri Veliz, Baylor St Luke’s Medical Center, Houston, TX: Ivan Rosas, Nicola Hanalia, Kalpalatha Guntupalli, Fernando Poli de Frias, Laura Bertrand, Mustafa Atik, Hinali Zaveri, Baylor Scott & White Medical Center – College Station, College Station, TX: Robert L. Gottlieb, Timothy M. Byrd, Seth J. Sullivan, Marvin Dao, Samantha Beever, Vanessa Hoelscher, Rachel Lovett, Baylor Scott & White Medical Center – Irving, Irving, TX: Robert L. Gottlieb, Steven G. Davis, Robert M. Engle, Tania Purubayast, Jon Thammoavong, Brittany Garcia, Melissa Ainslie, Alyksa Boudreau, Krista Duque, Demi Liia, Dreda Preece, Noelia Ramirez, Felicity Vaughn, Mary Wallace, Decolia Washington, Amy C. Thomas, Susan Fedorosan, Chad Samuelson, Baylor Scott & White Medical Center – Plano, Plano, TX: Robert L. Gottlieb, J. Michael DiMaio, Axiom Azfal, Katrina Youngblood, Julie McCraken, Christine Brooks, Penni Dolton, Raven Harding, Anne LaRock, Pauline Nathari, Jacqueline Nguyen, Baylor Scott & White Medical Center – Temple, Temple, TX: Robert L. Gottlieb, John Midtur, Thomas Delmas, Shhekar Ghamsare, Heath White, Ludmila Ploskaryan, Rohini Bagewadi, Wanda Fikes, Mackenzie Morquecho, Dayna Sawyer, Jessica Christian, Katelyn Brockway, John Thompson, Stefani Lehman, Martha Zayed, Baylor University Medical Center, Dallas, TX: Robert L. Gottlieb, Cedric W. Spak, Shelley A. Hall, Mark Hupbert, Janet Jernro, Katalin Martits-Chalangari, Erica Lusk, Dianna Robinson, Sarah Burris, Maris Adams, Rebecca Baker, Giselle Carino, Laura Clariday, Tanquisha Coleman, Rania El Tomi, Nazia Iram, Felecia Jones, Catherine Kumwenda-Wilson, Kira Leonard, Eva Patel, Shannon Perez, Robert Roven, Careen Swift, Emma Turner, Samantha Wang, Aaron Killian, Adriana Palacios, Edilia Solis, Baystate Medical Center, Springfield, MA: Daniel Skiest, Hans Schlich, Abigail Orenstein, Armando Paez, Mark Tidwold, Durane Walker, Serell Thornton, Ben Taub General Hospital, Houston, TX: Ivan Rosas, Nicola Hanalia, Kalpalatha Guntupalli, Fernando Poli de Frias, Mustafa Atik, Laura Bertrand, Benazir Khan, Juan Rodriguez, Rene Plascencia, Haniel Zavali, Boston Medical Center, Boston, MA: Nina H. Lin, Archana Asundi, Tara Bouton, Samantha Roche, Yunhan Chen, Athena Schmidt, Jennifer Bombard; Henry Ford Medical Center, Detroit, MI: Mayur Ramesh, George Alangaden, Katrina Williams, Melissa Reki, Victoria Churchill, Hoag Hospital Newport Beach and Irvine, Irvine, CA: Philip Robinson, Rosie Blancahs, Braharn Alavynejad, Neema Aghamohammadi, Mazda Aghamohammadi, Martin Fee, Nathan Gilmore, Farzad Sarafian, Ursham Shah, Laura Heim, Laurie Hendricks, Marcus Breit, Rachel Romaniski, Adrienne Swietlikowski, Wendy Price, Atessa Kiani, Holy Cross Health, Fort Lauderdale, FL: Zdenka Segota, Stephen Renae, Margaret Juliana Gorensek, Carlos Octavio Guerra, Frank Peter Hull, Ricardo R. Reyes, E. Tracey Melhuisn, Denise Pichardo, Eileen Georg, Christine Lepurage, Houston Methodist Hospital, Houston, TX: Deepa Guor, Katherine Perez,
References

1. World Health Organization. Coronavirus disease (COVID-19) pandemic. https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed July 6, 2021

2. World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance 13 March 2020. https://www.who.int/docs/default-source/coronaviruseclinical-management-of-novel-cov.pdf. Accessed July 6, 2021

3. World Health Organization. Coronavirus disease (COVID-19) weekly epidemiological update and weekly operational update. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed July 6, 2021

4. Bain W, Yang H, Shah FA, Suber T, Drohan C, Al-Yousif N et al (2021) COVID-19 versus non-COVID ARDS: comparison of demographics, physiologic parameters, inflammatory biomarkers and clinical outcomes. Ann Am Thorac Soc. https://doi.org/10.1513/AnnalsATS.202008-1026OC

5. McElvaney OJ, McEvoy NL, McElvaney OF, Carroll TP, Murphy MP, Dunlea DM et al (2020) Characterization of the inflammatory response to severe COVID-19 illness. Am J Respir Crit Care Med 202:812–821. https://doi.org/10.1164/rccm.202005-1583OC

6. The REMAP-CAP Investigators (2021) Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med 384:1813–1826. https://doi.org/10.1056/NEJMoa2007764

7. RECOVERY Collaborative Group (2021) Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 397:1637–1645

8. Salama C, Han J, Yao L, Weiss WG, Kramer B, Neidhart JD et al (2021) Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med 384:497–511. https://doi.org/10.1056/NEJMoa2100433

9. Spinner CD, Gottlieb RL, Criner GJ, Arribas Lopez JR, Cattelan AM, Soriano Vladiomirou A et al (2020) Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA 324:1048–1057. https://doi.org/10.1001/jama.2020.16349

10. National Institutes of Health. The COVID-19 Treatment Guidelines Panel's statement on the use of tocilizumab for the treatment of COVID-19. March 5, 2021. https://files.covid19treatmentguidelines.nih.gov/guidelines/archive/updated-statement-on-tocilizum-03-05-2021.pdf. Accessed July 6, 2021

11. Butler E, Warra Munch M, Venkatase B (2021) Time for tocilizumab in COVID-19? Intensive Care Med 47:692–694

12. Salvarani C, Dolci G, Massani M, Merlo DF, Cavuto S, Savoldi L et al (2021) Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med 181:24–31. https://doi.org/10.1001/jama.2020.6615

13. The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group (2021) Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA. https://doi.org/10.1001/jama.2021.11330

14. World Health Organization (2020) A living WHO guideline on drugs for covid-19. BMJ 370:m3379. https://doi.org/10.1136/bmj.m3379

15. Gordon CJ, Tchesnokov EP, Woolner E, Perry JK, Feng JY, Porter DP et al (2020) Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem 295:6785–6797. https://doi.org/10.1074/jbc.RA120.013679

16. Tchesnokov EP, Gordon CJ, Woolner E, Kocinkova D, Perry JK, Feng JY et al (2020) Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action. J Biol Chem 295:16156–16165. https://doi.org/10.1074/jbc.AC120.015720

17. Beigel JH, Tomashek KM, Dodd LE, Mheita AK, Zingman S, Kalil AC et al (2020) Remdesivir for the treatment of Covid-19—final report. N Engl J Med 383:1813–1826. https://doi.org/10.1056/NEJMoa2007764

18. Gordon CJ, Tchesnokov EP, Woolner E, Kocinkova D, Perry JK, Feng JY et al (2020) Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action. J Biol Chem 295:16156–16165. https://doi.org/10.1074/jbc.AC120.015720

19. Beigel JH, Tomashek KM, Dodd LE, Mheita AK, Zingman S, Kalil AC et al (2020) Remdesivir for the treatment of Covid-19—final report. N Engl J Med 383:1813–1826. https://doi.org/10.1056/NEJMoa2007764

20. Pan H, Petru P, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Karim QA et al (2021) Repurposed antiviral drugs for Covid-19—interim WHO solidarity trial results. N Engl J Med 384:497–511. https://doi.org/10.1056/NEJMoa2023184

21. Bain W, Yang H, Shah FA, Suber T, Drohan C, Al-Yousif N et al (2021) COVID-19 versus non-COVID ARDS: comparison of demographics, physiologic parameters, inflammatory biomarkers and clinical outcomes. Ann Am Thorac Soc. https://doi.org/10.1513/AnnalsATS.202008-1026OC